249 institutions hold shares in Ascendis Pharma A/S (ASND), with 13.97k shares held by insiders accounting for 0.03% while institutional investors hold 103.11% of the company’s shares. The shares outstanding are 53.52M, and float is at 43.77M with Short Float at 6.88%. Institutions hold 103.09% of the Float.
The top institutional shareholder in the company is Price (T.Rowe) Associates Inc with over 6.62 million shares valued at $1.1 billion. The investor’s holdings represent 12.31% of the ASND Shares outstanding. As of Dec 30, 2020, the second largest holder is RA Capital Management, L.P. with 5.87 million shares valued at $978.22 million to account for 10.91% of the shares outstanding. The other top investors are Artisan Partners Limited Partnership which holds 5.77 million shares representing 10.73% and valued at over $961.91 million, while FMR, LLC holds 9.94% of the shares totaling 5.34 million with a market value of $890.87 million.
Ascendis Pharma A/S (NASDAQ: ASND) is -14.88% lower on its value in year-to-date trading and has touched a low of $119.11 and a high of $183.98 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The ASND stock was last observed hovering at around $138.27 in the last trading session, with the day’s gains setting it 3.69% off its average median price target of $158.86 for the next 12 months. It is also 21.54% off the consensus price target high of $180.93 offered by 14 analysts, but current levels are -1.67% lower than the price target low of $139.63 for the same period.
Currently trading at $141.96, the stock is 10.36% and 1.94% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.22 million and changing 2.67% at the moment leaves the stock -6.41% off its SMA200. ASND registered 6.16% gain for a year compared to 6-month loss of -13.56%. The firm has a 50-day simple moving average (SMA 50) of $132.92 and a 200-day simple moving average (SMA200) of $154.55.
The stock witnessed a 10.35% gain in the last 1 month and extending the period to 3 months gives it a -8.64%, and is 7.67% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.65% over the week and 3.56% over the month.
Ascendis Pharma A/S (ASND) has around 482 employees, a market worth around $7.62B and $8.40M in sales. Distance from 52-week low is 19.18% and -22.84% from its 52-week high. The company has generated returns on investments over the last 12 months (-35.50%).
Ascendis Pharma A/S (ASND) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Ascendis Pharma A/S (ASND) is a “Buy”. 14 analysts offering their recommendations for the stock have an average rating of 1.60, where 1 rate it as a Hold and 0 think it is a “Overweight”. 13 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Ascendis Pharma A/S is expected to release its quarterly report on 09/01/2021 and quarterly earnings per share for the current quarter are estimated at -$2.07 with sales reaching $2.28M over the same period.The EPS is expected to shrink by -76.60% this year, but quarterly earnings will post 253.50% year-over-year. Quarterly sales are estimated to grow 8.10% in year-over-year returns.
Ascendis Pharma A/S (ASND): Who are the competitors?
The company’s main competitors (and peers) include Agenus Inc. (AGEN) that is trading 12.77% up over the past 12 months. Amgen Inc. (AMGN) is -0.42% down on the 1-year trading charts. Short interest in the company’s stock has fallen -5.61% from the last report on Apr 14, 2021 to stand at a total of 3.01 million short shares sold with a short interest ratio of 12.44.